Welcome to our dedicated page for Elanco Animal Health SEC filings (Ticker: ELAN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Elanco Animal Health filings document the disclosures of a public animal health company focused on products for farm animals and pets. The record includes Form 8-K reports on operating results, clinical or regulatory matters, capital-structure updates, credit-facility amendments, investor presentations, and restructuring-related exit or disposal activities.
Elanco's proxy materials describe board composition, shareholder voting matters, executive compensation, equity awards, and governance practices. Its filings also provide formal disclosure around material events, financial reporting, and the capital arrangements that support the company's global animal health operations.
On 27 June 2025, Elanco Animal Health Inc. (ELAN) disclosed in a Form 4 that Executive Vice President of U.S. Pet Health & Global Digital Transformation Rajeev A. Modi received 98.9937 deferred stock units (DSUs) at a reference price of $14.29 under the company’s Executive Deferral and Stock Match Plan. Each DSU converts into one common share or its cash equivalent upon settlement after employment ends or in a predetermined future year. The award is classified as transaction code “A,” meaning it is a compensation grant rather than an open-market purchase. Modi now directly holds 6,460.6903 DSUs; no shares were sold or otherwise disposed. The grant is small—worth roughly $1.4 thousand—and does not materially alter insider ownership or the company’s share count, but it marginally reinforces management-shareholder alignment.
Elanco Animal Health Inc. (ELAN) – Form 4 insider filing
On 27 June 2025, President & CEO Jeffrey N. Simmons acquired 193.7887 deferred stock units (DSUs) under the company’s Executive Deferral and Stock Match Plan at a reference price of $14.29. Each DSU represents the right to receive either one common share or a cash equivalent upon settlement, which occurs after employment ends or in a pre-elected future year. Following the transaction, Simmons now beneficially owns 16,849.4516 DSUs, held directly.
The filing discloses no open-market purchases or sales; the units were issued as part of a compensation-related deferral program. The size of the award—worth roughly US$2.8 thousand based on the reference price—is immaterial relative to Elanco’s market capitalisation and Simmons’ existing holdings, but it does incrementally increase insider ownership.
Elanco Animal Health (NYSE:ELAN) filed an 8-K reporting a First Amendment to its Receivables Loan Agreement with Rabobank. The amendment extends the accounts-receivable securitization facility’s maturity from Aug 3 2026 to Jun 26 2028, keeps Elanco as performance guarantor, Elanco SPEAR LLC as borrower, and Elanco US as servicer.
The filing is deemed a material definitive agreement (Item 1.01) and a direct financial obligation/off-balance-sheet arrangement (Item 2.03). Financial amounts were not disclosed, but the longer tenor is expected to improve liquidity and refinancing flexibility. Investors should review Exhibit 10.1 for precise covenant changes.